肝癌适形放疗后放射性肝病的剂量体积直方图分析

摘要/Abstract

摘要： 目的放射性肝病(RILD)是原发性肝癌(PLC)大分割三维适形放射治疗(3DCRT)后最严重的并发症。然而,放射性肝病尚无有效的预测因素。本研究旨在探讨影响肝硬化Child-Pugh A级PLC患者大分割3DCRT后RILD的剂量学因素。方法2000年8月至2007年6月采用8MVX线直线加速器对114例肝硬化Child-Pugh A级PLC患者放疗符合入组条件进入本研究,其中男104例,女10例,中位年龄45岁(23～79岁)。B超或CT提示有门脉癌栓者22例,GTV为(378.3±308.1)cm3,分割剂量4～6Gy(中位4.6Gy),每周3次,隔日1次。肿瘤剂量40～68Gy(中位53Gy),总疗程3～6周(中位4周)。38例患者放疗前接受过经动脉化疗栓塞术(TACE)治疗,所有病人均有包括DVH图在内的完整的剂量学数据。结果所有患者3DCRT治疗后中位随访期19个月(1～79个月),发生RILD9例,发生率为7.9%(9/114)。单因素分析发现GTV和V5、V10、V15、V20、V25、V30、V35、V40与RILD相关;多因素分析发现GTV和V20是独立影响因素(P=0.015和0.003)。V20=48.5%作为耐受剂量,预测RILD准确度达0.763,敏感度为0.889,特异度为0.752。结论对于行3DCRT治疗后的肝硬化Child-PughA级的PLC患者,V20是预测RILD有独特意义的影响因素。

关键词: 肝肿瘤, 放射治疗, 适形放射治疗, 大分割, 放射性肝病

Abstract: Objective Radiation-induced liver disease (RILD) has been considered as the most severe complication in liver irradiation.However,RILD does not have effective predictors.This study was to identify dosimetric predictors for RILD in primary liver carcinoma (PLC) patients with Child-Pugh grade A cirrhosis after being treated with hypofractionated conformal radiotherapy (CRT).Methods Between August 2000 and June 2007,a total of 114 eligible patients were included.The median age was 45 years (23~79 years).Portal vein thrombosis (PVT) was detected in 22 patients.The mean gross tumor volume (GTV) was (378.3 ± 308.1) cm3.A median dose of 53 Gy (40~68 Gy) was delivered to the PLC by hypofractionated CRT (three fractions per week) with a median fraction size of 4.6 Gy (4~6 Gy).Thirty-eight patients had previously received transcatheter arterial chemoembolization.All patients had intact treatment planning data,including liver dose-volume histograms before treatment.Results Patients were followed up for 1-79 months (median 19 months) after completion of the irradiation.RILD was diagnosed in 9 (7.9%) patients.Univariate analyses revealed that GTV and the percent of normal liver volume exceeding 5-40 Gy (V5-40) were related to the risk of developing RILD.Multivariate analyses showed that only GTV (P=0.015) and V20 (P=0.003) were independent predictors.When using V20= 48.5% as tolerated dose to predict RILD,the accuracy,sensitivity and specificity was 76.3%,88.9% and 75.2%,respectively.Conclusions V20 is a unique significant dosimetric predictor to evaluate RILD risks for PLC patients with Child-Pugh grade A cirrhosis after hypofractionated CRT.

Key words: Liver neoplasm, Radiotherapy, Conformal radiotherapy, Hypofractionation, Radiation-induced liver disease

黄华忠;李业飞;梁世雄;. 肝癌适形放疗后放射性肝病的剂量体积直方图分析[J]. 中国癌症防治杂志, 2009, 1(04): 313-317.

HUANG Hua-zhong,LI Ye-fei,LIANG Shi-xiong.. Dose-volume histogram analysis on radiation-induced liver disease (RILD) after conformal radiotherapy for primary liver carcinoma[J]. Chinese Journal of Oncology Prevention and Treatment, 2009, 1(04): 313-317.

参考文献

1Colombo M.Hepatocellular carcinoma[J].J Hepatol,1992,15:225-236. 2Kiyosawa K,Umemura T,Ichijo T,et al.Hepatocellular carcinoma:recent trends in Japan[J].Gastroenterology,2004,127(5Suppl1):17-26. 3Esnaola NF,Mirza N,Lauwers GY,et al.Comparison of clinicopathologic char-acteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States,France,and Japan[J].Ann Surg,2003,238:711-719. 4Makuuchi M,Sano K.The surgical approach to HCC:our progress and results in Japan[J].Liver Transpl,2004,10(2Suppl1):46-52. 5Uno T,Itami J,Shiina T,et al.Radiation therapy in patients with unresectable hepatocellular carcinoma[J].Cancer Chemother Pharmacol,1992,31(Suppl):106-110. 6Seong J,Keum KC,Han KH,et al.Combined transcatheter arterial chemoembo-lization and local radiotherapy of unresectable hepatocellular carcinoma[J].Int J Radiat Oncol Biol Phys,1999,43:393-397. 7Matsuura M,Nakajima N,Arai K,et al.The usefulness of radiation therapy for hepatocellular carcinoma[J].Hepatogastroenterology,1998,45:791-796. 8Cheng JC,ChuangVP,ChengSH,etal.Local radiotherapy with or withouttran-scatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma[J].Int J Radiat Oncol Biol Phys,2000,47:435-442. 9Lawrence TS,Ten-Haken RK,Kessler ML,et al.The use of3-D dose volume a-nalysis to predictradiation hepatitis[J].IntJ RadiatOncol Biol Phys,1992,23:781-788. 10Dawson LA,McGinn CJ,Normolle D,et al.Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malig-nancies[J].J Clin Oncol,2000,18:2210-2218. 11Robertson JM,Lawrence TS,Dworzanin LM,et al.Treatment of primary hepa-tobiliary cancers with conformal radiation therapy and regional chemotherapy[J].J Clin Oncol,1993,11:1286-1293. 12Liang SX,Zhu XD,Lu HJ,etal.Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma[J].Cancer,2005,103:2181-2188. 13Cheng JC,Wu JK,Lee PC,etal.Biologic susceptibility of hepatocellular carci-noma patients treated with radiotherapy to radiation-induced liver disease[J].Int J Radiat Oncol Biol Phys,2004,60:1502-1509. 14Liang SX,Zhu XD,Xu ZY,et al.Radiation-induced liver disease in three-di-mensional conformal radiation therapy for primary liver carcinoma:the risk fac-tors and hepatic radiation tolerance[J].Int J Radiat Oncol Biol Phys,2006,65:426-434. 15Xu ZY,Liang SX,Zhu J,et al.Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional confor-mal radiation therapy for primary liver carcinoma[J].Int J Radiat Oncol Biol Phys,2006,65:189-195. 16杨秉辉.原发性肝癌[M].第五分册,见中国抗癌协会编:新编常见恶性肿瘤诊治规范(合订本).北京:中国协和医科大学出版社,1999:389-479. 17Dawson LA,Ten Haken RK,Lawrence TS.Partial irradiation of the liver[J].Semin Radiat Oncol,2001,11:240-246. 18Cheng JC,Wu JK,Huang CM,et al.Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carci-noma:Dosimetric analysis and implication[J].Int J Radiat Oncol Biol Phys,2002,54:156-162. 19Dawson LA,Normolle D,Balter JM,et al:Analysis of radiation-induced liver disease using the Lyman NTCP model[J].Int J Radiat Oncol Biol Phys,2002,53:810-821.

[1]	中国抗癌协会整合肿瘤学分会, 中国抗癌协会肿瘤标志专业委员会. 非小细胞肺癌放疗联合免疫治疗中国专家共识（2024版）[J]. 中国癌症防治杂志, 2024, 16(5): 505-515.
[2]	王勇, 周玉玲, 周琼辉, 曾彪, 胡英. 3D打印补偿膜在乳腺癌即刻乳房重建术后放疗中的应用[J]. 中国癌症防治杂志, 2024, 16(1): 96-100.
[3]	成超, 李杰. 放疗联合免疫检查点抑制剂治疗肺癌致放射⁃免疫相关性肺炎的研究进展[J]. 中国癌症防治杂志, 2022, 14(6): 687-692.
[4]	侯光营, 苗珺珺, 胡建伟, 郜蕾, 张永侠, 袁香坤. 3D打印微创导向模板插植放射治疗联合深部热疗治疗局部晚期宫颈癌的疗效分析[J]. 中国癌症防治杂志, 2022, 14(1): 76-81.
[5]	王梓萌, 向作林 . 立体定向放射治疗肝脏转移瘤的临床疗效[J]. 中国癌症防治杂志, 2021, 13(6): 641-646.
[6]	何美霖, 易俊林. 鼻咽癌精准放化疗个体化决策思考[J]. 中国癌症防治杂志, 2020, 12(4): 384-390.
[7]	高琨, 李力. 放射治疗在妊娠滋养细胞肿瘤治疗中的价值[J]. 中国癌症防治杂志, 2020, 12(2): 159-162.
[8]	明淑凤, 童光武, 童肖广, 黄卫彬, 吴志权. 个性化容积旋转调强准直器角度优化在宫颈癌放疗中的应用[J]. 中国癌症防治杂志, 2019, 11(5): 421-425.
[9]	金明朋,尹纯,尚英英,曹海燕,吉晓莹,任婷婷,邢金良,吴有盛. NCLX介导的线粒体钙稳态对肝癌细胞生长的影响[J]. 中国癌症防治杂志, 2018, 10(6): 420-426.
[10]	鞠佳霓,明志勇,代全楷,李科志,黄山,何剑波,邬国斌,陈闯. 岩黄连水提物对肝癌HepG2细胞增殖和迁移能力的影响及其可能机制[J]. 中国癌症防治杂志, 2018, 10(6): 434-438.
[11]	谭妮,曹骥,杨春,郑海平,欧超. 基于RNA-seq分析黄曲霉毒素B1诱导大鼠肝癌的可变剪接事件[J]. 中国癌症防治杂志, 2018, 10(5): 356-360.
[12]	吴玲红,黄天壬,邓伟,黄志碧,国娇,黄月莹. 中国人群HBV基因型及亚型与肝细胞癌相关性的Meta分析[J]. 中国癌症防治杂志, 2018, 10(5): 365-370.
[13]	倪路,赵志强,高越,母汉正,齐云飞. FOXK1对肝癌高转移细胞系Huh7侵袭和迁移能力的影响[J]. 中国癌症防治杂志, 2018, 10(4): 286-289.
[14]	谭宝高,刘彪. 3.0T MR动脉自旋标记技术对早期原发性肝癌的诊断价值[J]. 中国癌症防治杂志, 2018, 10(4): 310-313.
[15]	梁霞,李龄. 鼻咽癌IMRT自适应放疗研究进展[J]. 中国癌症防治杂志, 2018, 10(4): 338-341.